Open access
719
Views
26
CrossRef citations to date
0
Altmetric
Review
A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
David B Clemow1 Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]
, Chris Bushe2 Eli Lilly, Windlesham, UK
, Michele Mancini3 Eli Lilly Italia S.p.A., Sesto Fiorentino, Italy
, Michael H Ossipov4 inVentiv Health Clinical, LLC, Blue Bell, PA, USA
& Himanshu Upadhyaya1 Eli Lilly and Company, Indianapolis, IN, USA
Pages 357-371
|
Published online: 03 Feb 2017
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.